根据药明康德在JPM大会上披露的演示材料显示，截至2024年末，公司临床阶段GLP-1药物数量已快速增长至20个，同比增长54%。相比之下，同期全球临床阶段GLP-1药物(包括小分子和多肽)总数为85个，同比增长37%。根据全球行业咨询及市场调研机构Evaluate Pharma提供的数据，预计到2030年，GLP-1药物的全球销售额将达到1260亿美元，是2023年销售额的3.4倍。
Source Link根据药明康德在JPM大会上披露的演示材料显示，截至2024年末，公司临床阶段GLP-1药物数量已快速增长至20个，同比增长54%。相比之下，同期全球临床阶段GLP-1药物(包括小分子和多肽)总数为85个，同比增长37%。根据全球行业咨询及市场调研机构Evaluate Pharma提供的数据，预计到2030年，GLP-1药物的全球销售额将达到1260亿美元，是2023年销售额的3.4倍。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.